SMS Pharmaceuticals Limited (BOM:532815)
India
· Delayed Price · Currency is INR 249.95
-3.95 (-1.56%)
At close: Jun 5, 2025
SMS Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Operating Revenue | 7,827 | 7,093 | 5,221 | 5,199 | 5,632 | Upgrade
|
| Other Revenue | 62.24 | - | - | - | - | Upgrade
|
| Revenue | 7,890 | 7,093 | 5,221 | 5,199 | 5,632 | Upgrade
|
| Revenue Growth (YoY) | 11.24% | 35.86% | 0.42% | -7.69% | 35.93% | Upgrade
|
| Cost of Revenue | 5,234 | 4,983 | 3,900 | 3,309 | 3,797 | Upgrade
|
| Gross Profit | 2,656 | 2,109 | 1,321 | 1,890 | 1,835 | Upgrade
|
| Selling, General & Admin | 800.84 | 658.08 | 547.63 | 515.16 | 414.94 | Upgrade
|
| Other Operating Expenses | 402.64 | 276.02 | 224.85 | 222.38 | 202.34 | Upgrade
|
| Operating Expenses | 1,547 | 1,249 | 1,094 | 1,059 | 840.09 | Upgrade
|
| Operating Income | 1,109 | 860.1 | 226.98 | 830.73 | 994.62 | Upgrade
|
| Interest Expense | -185.41 | -226.18 | -209.94 | -181.57 | -102.54 | Upgrade
|
| Interest & Investment Income | - | 7.58 | 7.75 | 5.6 | 3.14 | Upgrade
|
| Earnings From Equity Investments | 17.37 | 6.26 | -109.43 | -56.61 | 15.62 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 28.98 | 39.05 | 25.8 | 5.71 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -9.78 | -9.8 | 4.47 | 10.34 | Upgrade
|
| EBT Excluding Unusual Items | 940.74 | 666.96 | -55.4 | 628.42 | 926.9 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.37 | -0.54 | -0.04 | -0.08 | Upgrade
|
| Pretax Income | 940.74 | 667.33 | -55.94 | 628.38 | 926.82 | Upgrade
|
| Income Tax Expense | 249.39 | 169.07 | 14.65 | 6.18 | 301.55 | Upgrade
|
| Earnings From Continuing Operations | 691.35 | 498.26 | -70.59 | 622.2 | 625.27 | Upgrade
|
| Minority Interest in Earnings | 0.01 | - | - | - | - | Upgrade
|
| Net Income | 691.36 | 498.26 | -70.59 | 622.2 | 625.27 | Upgrade
|
| Net Income to Common | 691.36 | 498.26 | -70.59 | 622.2 | 625.27 | Upgrade
|
| Net Income Growth | 38.75% | - | - | -0.49% | 98.04% | Upgrade
|
| Shares Outstanding (Basic) | 85 | 85 | 85 | 85 | 85 | Upgrade
|
| Shares Outstanding (Diluted) | 85 | 85 | 85 | 85 | 85 | Upgrade
|
| Shares Change (YoY) | 0.09% | - | - | - | - | Upgrade
|
| EPS (Basic) | 8.16 | 5.89 | -0.83 | 7.35 | 7.39 | Upgrade
|
| EPS (Diluted) | 8.16 | 5.89 | -0.83 | 7.35 | 7.39 | Upgrade
|
| EPS Growth | 38.64% | - | - | -0.49% | 98.04% | Upgrade
|
| Free Cash Flow | -416.71 | -20.35 | -74.71 | 178.12 | -612.96 | Upgrade
|
| Free Cash Flow Per Share | -4.92 | -0.24 | -0.88 | 2.10 | -7.24 | Upgrade
|
| Dividend Per Share | - | 0.400 | 0.300 | 0.300 | 0.300 | Upgrade
|
| Dividend Growth | - | 33.33% | - | - | 20.00% | Upgrade
|
| Gross Margin | 33.66% | 29.74% | 25.30% | 36.35% | 32.58% | Upgrade
|
| Operating Margin | 14.05% | 12.13% | 4.35% | 15.98% | 17.66% | Upgrade
|
| Profit Margin | 8.76% | 7.03% | -1.35% | 11.97% | 11.10% | Upgrade
|
| Free Cash Flow Margin | -5.28% | -0.29% | -1.43% | 3.43% | -10.88% | Upgrade
|
| EBITDA | 1,452 | 1,169 | 541.39 | 1,142 | 1,207 | Upgrade
|
| EBITDA Margin | 18.41% | 16.48% | 10.37% | 21.97% | 21.43% | Upgrade
|
| D&A For EBITDA | 343.37 | 308.68 | 314.41 | 311.36 | 212.32 | Upgrade
|
| EBIT | 1,109 | 860.1 | 226.98 | 830.73 | 994.62 | Upgrade
|
| EBIT Margin | 14.05% | 12.13% | 4.35% | 15.98% | 17.66% | Upgrade
|
| Effective Tax Rate | 26.51% | 25.34% | - | 0.98% | 32.54% | Upgrade
|
| Revenue as Reported | 7,890 | 7,137 | 5,270 | 5,251 | 5,666 | Upgrade
|
| Advertising Expenses | - | 15.86 | 8.59 | 4 | 2.18 | Upgrade
|
Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.